SCHEMBL6492344

SCHEMBL6492344

CCOC(=O)Cc1c(O)nc2cccc(Cl)c2c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.42
LCK P06239 1/20 0.42
MAPK1 P28482 3/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
NLRP3 Q96P20 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
KDM4E B2RXH2 4/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PRNP P04156 1/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
AHR P35869 1/20 0.38
PARP1 P09874 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HPGD P15428 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499160 0.87 HSD17B10 (0.44) HSD17B10MAPK1USP2TSHRNLRP3
SCHEMBL7059144 0.83 ELANE (0.44) HSD17B10MAPK1USP2TSHRTRPM8
SCHEMBL7057147 0.82 KDM4E (0.39) HSD17B10LCKMAPK1USP2TSHR
SCHEMBL7061260 0.81 KDM4E (0.40) HSD17B10LCKMAPK1USP2TSHR
SCHEMBL6498960 0.79 HSD17B10 (0.50) HSD17B10MAPK1USP2TSHRTRPM8
SCHEMBL7055136 0.79 KDM4E (0.38) HSD17B10LCKMAPK1USP2TSHR
SCHEMBL7056212 0.79 KDM4E (0.41) HSD17B10MAPK1USP2TSHRTRPM8
SCHEMBL7057483 0.78 KDM4E (0.39) HSD17B10MAPK1USP2TSHRKDM4E
SCHEMBL7055682 0.77 KDM4E (0.39) HSD17B10MAPK1USP2TSHRTRPM8
SCHEMBL1429298 0.76 AKR1B1 (0.55) HSD17B10MAPK1NLRP3KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908932-B2 Cancer therapy ICONIX PHARMACEUTICALS, INC. (US) 2005-06-21 US disclosed
US-20030149074-A1 Modulators of phosphoinositide 3-kinase ENTELOS HOLDING CORP. 2003-08-07 US disclosed
WO-2003035618-A2 MODULATORS OF PHOSPHOINOSITIDE 3-KINASE ICONIX PHARMACEUTICALS, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149074-A1 Modulators of phosphoinositide 3-kinase PIK3R1, PIK3R3, PIK3R4 HSD17B10 894/4885LCK 488/4885MAPK1 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.